In contrast, post-COVID-19 myocarditis shows outcomes similar to conventional myocarditis<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Aug. 29, 2024 (HealthDay News) — Patients with post-COVID-19 mRNA vaccination myocarditis show a lower frequency of cardiovascular complications than those with conventional myocarditis or post-COVID-19 myocarditis at 18 months, according to a study published online Aug. 26 in the\u00a0Journal of the American Medical Association<\/em>.<\/p>\n Laura Semenzato, from the French National Agency for the Safety of Medicines and Health Products and French National Health Insurance, and colleagues examined the prognosis and management of post-COVID-19 mRNA vaccination myocarditis compared to other types of myocarditis during 18 months of follow-up. The analysis included 4,635 individuals who were hospitalized for myocarditis, including 558 with postvaccine myocarditis, 298 with post-COVID-19 myocarditis, and 3,779 with conventional myocarditis.<\/p>\n The researchers found that patients with postvaccine myocarditis were younger than those with post-COVID-19 and conventional myocarditis (mean age, 25.9, 31.0, and 28.3 years, respectively) and were more frequently men (84, 67, and 79 percent, respectively). There was a lower standardized incidence of the composite clinical outcome (hospital readmission for myopericarditis, other cardiovascular events, and all-cause death) for patients with postvaccine myocarditis than those with conventional myocarditis (weighted hazard ratio, 0.55; 95 percent confidence interval, 0.36 to 0.86). Individuals with post-COVID-19 myocarditis had similar outcomes to conventional myocarditis (weighted hazard ratio, 1.04; 95 percent confidence interval, 0.70 to 1.52). Postvaccine myocarditis and post-COVID-19 myocarditis showed a similar trend for frequency of medical procedures and drugs prescribed posthospital discharge to that of patients with conventional myocarditis.<\/p>\n “Affected patients, mainly healthy young men, may require medical disease management for up to several months after hospital discharge,” the authors write.<\/p>\n